Butilhioscina (Butylscopolamine)
Active Ingredient: Butylscopolamine
Dosage: 10 mg
Route of Administration: Oral
Dosage Form: Tablets
Quantity per package: 10 pills
Availability: Out of stock
Why is Butylscopolamine not used in the USA?
In the United States, Butylscopolamine is not commonly used or approved for over-the-counter sales, likely due to the availability of alternative antispasmodic drugs that have been more extensively studied and approved by the FDA for similar uses.
Similar/Alternative Drugs for Butylscopolamine Sold in the USA
Here are similar antispasmodic and muscle relaxant drugs available in the USA, grouped by their primary therapeutic use, from your initial list:
Antispasmodics for GI and Urinary Tract:
Muscle Relaxants for Pain Relief:
Urogenital Spasm Relief:
What is Butilhioscina?
Butilhioscina is a medication used to relieve abdominal pain, esophageal spasms, renal colic, and bladder spasms. It is also used to enhance respiratory secretions at the end of life. It works by blocking the action of acetylcholine at muscarinic receptors in the smooth muscle, thus reducing muscle contractions and the pain associated with spasms.
Indications
- Irritable colon in which another treatment has failed;
- Spasmodic pathologies of the biliary tract;
- Urinary diseases;
- Dysmenorrhea or nocturnal enuresis;
- As an adjuvant to anesthesia (parenteral) to prevent salivation and excessive secretions from the respiratory tract, or to produce amnesia and reduce arousal;
- Prophylaxis of arrhythmias caused by surgery or suxamethonium;
- Treatment and prophylaxis of motion sickness.
Dosage and administration
Tablets are taken orally. Take 0.25 to 0.8mg one hour before requiring the antiemetic effect. Antiemetic (parenteral) and antimuscarinic (parenteral) 0.3 to 0.6g in a single dose; children, 0.006mg / kg body weight. Anesthesia adjuvant: a) sedation-hypnosis: 0.6mg three or four times a day; b) amnesia: 0.32 to 0.65mg. Prophylaxis of salivation and excessive respiratory tract secretions in anesthesia: children: (4 to 7 months) 0.1mg; (7 months to 3 years) 0.15mg; (3 to 8 years) 0.2mg; (8 to 12 years old) 0.3mg. Transdermal forms of use as antivertiginous and antiemetic: 0.5mg that are released within three days.
Popularity and Usage by Country
Butilhioscina is popular in several countries, particularly in Latin America and parts of Europe, where it is widely used for its effectiveness in treating spasm-related conditions without the central nervous system side effects associated with other antispasmodics. Its popularity in these regions is due to its availability, cost-effectiveness, and established use in medical practice for these indications.
Contraindications
Hypersensitivity to belladonna derivatives (there may be a cross-reaction).
Side effects
Butilhioscina can cause drowsiness, lack of feeling of well-being, memory loss, sleep disturbances, confusion, dizziness, feeling faint, eye pain.
Overdose
Signs: severe tiredness, blurred vision, clumsiness and instability, confusion, shortness of breath, dizziness, severe drowsiness, fever, tachycardia, hallucinations, seizures, dry mouth, nose and pronounced throat.
Treatment: adsorbent carbon, gastric emptying. Slow administration of neostigmine or physostigmine (to reverse antimuscarinic symptoms), short-acting barbiturates or benzodiazepines (to control delirium and excitement). Symptomatic therapy.
Interaction
Butilhioscina can interact with glucocorticoids, corticotrophins, haloperidol (increased intraocular pressure), urinary alkalinizers, amantadine, tricyclic antidepressants, antihistamines, antimuscarinics, buclizine, cyclizine, cyclobenzaprine, disopyramide, ipratropium, loxapine, meclothiazine, phenothiazine, orphenadrine, inorganic acid, procainamide, thioxanthenes, antacids, antidiarrheals, antimyasthenics, cyclopropane, guanadrel, guanethidine, reserpine, ketoconazole, metoclopramide, MAOI, opioids, apomorphine, CNS depressants, parenteral lorazepam.